A recent article criticizing NeoStem's (NBS) lead program AMR-001 described skepticism that the Phase II trial will yield positive data later this year. Unfortunately, the points that were brought up mischaracterize the program, with a misunderstanding of some important basics of the trial. In this article, I will walk through the arguments surrounding AMR-001 and provide an alternative argument for why the Phase II trial is designed appropriately, is based on science, and should be more carefully considered.
AMR-001 is an autologous stem cell therapy derived from a patient's own bone-marrow cells, which is delivered through the intracoronary artery after a heart attack. The goal of treatment is restoration of blood flow, reducing cardiac tissue damage, and improving...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|